A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and diabetes counterpart Ozempic.
Read the full story at US Top News and Analysis →EUROS aggregates the world's financial press. The full article lives with the newsroom that reported it.